IP Library › Granted Patent US 11,369,314
Granted Patent B2
US 11,369,314 · App. 16/317,966 · Granted Jun 28, 2022

Biofouling prevention of wearable sensors and methods of use and calibration related thereto

Inventor: David Ledden (Elkhart, IN)
Assignee: Siemens Healthcare Diagnostics Inc.
A61B5/685A61B5/1451A61B5/1459A61B5/14532A61B5/6832A61K9/0021A61K31/192A61K31/573A61K31/616A61K31/722
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,369,314
App. No.
16/317,966
Filed
Jan 15, 2019
Granted
Jun 28, 2022
Kind
B2
Art Unit
3791
USPC
600/316
Abstract

Devices, kits, and methods for (a) determining the presence and/or concentration of at least one analyte(s) of interest present in a patient's fluid sample and devices and methods of calibration related thereto, and (b) preventing, mitigating, and/or eliminating biofouling of an indwelling, wearable biosensor are disclosed and/or claimed herein.

Claims (24)

1. An indwelling, wearable biosensor device for the continuous detection and monitoring of at least one analyte in a patient's fluid sample, the device comprising:

a microneedle array, the microneedle array comprising a plurality of microneedles constructed of at least one polymeric material, wherein the plurality of microneedles is imbedded in an epidermal tissue of a patient such that the plurality of microneedles is in continuous contact with a fluid sample of a patient, and further wherein at least one microneedle of the plurality of microneedles comprises at least one piezoelectric element;

a plurality of fluorophore sensors, wherein each fluorophore sensor is operatively associated with the at least one polymeric material of at least one microneedle of the plurality of microneedles, wherein each fluorophore sensor emits a fluorescent signal in the presence of at least one analyte that is indicative of a concentration of the at least one analyte in the fluid sample of the patient, and wherein each fluorophore sensor emits a constant signal when exposed to the fluid sample of the patient;

a substrate having a top portion and a bottom portion, wherein the microneedle array is permanently attached to the bottom portion of the substrate; and

a detector that receives signals emitted by the plurality of fluorophore sensors for calculating the concentration of the at least one analyte present in the fluid sample of the patient, and transmitting the concentration to an external device for diagnosis and evaluation of proposed treatments, and

wherein the detector comprises circuitry for receiving the signals generated by the at least one piezoelectric element, and further wherein the detector receives a first electrical signal generated by the at least one piezoelectric element and delivers a second electrical signal to the at least one piezoelectric element resulting in the vibration of the at least one piezoelectric element.

2. The device of claim 1 , wherein the at least one polymeric material is polyacrylamide.

3. The device of claim 1 , wherein the fluid sample is selected from the group consisting of interstitial fluid and blood.

4. The device of claim 1 , wherein the at least one piezoelectric element is selected from the group consisting of quartz, Berlinite, topaz, tourmaline, cane sugar, Rochelle salt, barium titanate, and lead zirconate titanate.

5. The device of claim 1 , wherein the bottom portion of the substrate comprises an adhesive for affixing the substrate to the epidermal tissue of the patient.

6. The device of claim 1 , wherein the at least one analyte present in the fluid sample of the patient is glucose.

7. The device of claim 1 , wherein each fluorophore sensor comprises at least one fluorophore selected from the group consisting of fluorescein, rhodamine, eosin, Oregon Green, Texas Red, coumarin derivatives, cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine, squaraine derivatives, pyridyoxazole, nitrobenzoxadiazole, benzoxadiazole, anthraquinones, pyrene derivatives, Nile Red, Nile Blue, cresyl violet, oxazine, proflavin, acridine orange, acridine yellow, auramine, crystal violet, malachite green, porphyrin, phtalocyanine, bilirubin, boronate, and combinations thereof.

8. The device of claim 1 , wherein the detector is selected from the group consisting of a microfluorometer, a filter fluorometer, or a spectrofluorometer.

9. An indwelling, wearable biosensor device for the continuous detection and monitoring of at least one analyte in a patient's fluid sample, the device comprising:

a microneedle array, the microneedle array comprising a plurality of microneedles constructed of at least one polymeric material, the plurality of microneedles comprising at least one calibration microneedle, wherein the plurality of microneedles is imbedded in an epidermal tissue of a patient such that the plurality of microneedles is in continuous contact with a fluid sample of a patient;

a plurality of fluorophore sensors, wherein each fluorophore sensor is operatively associated with the at least one polymeric material of at least one microneedle of the plurality of microneedles, wherein each fluorophore sensor emits a fluorescent signal in the presence of at least one analyte that is indicative of a concentration of the at least one analyte present in the fluid sample of the patient, and further wherein each of the plurality of analyte sensors emits a constant signal when exposed to the fluid sample of the patient;

a substrate having a top portion and a bottom portion, wherein the microneedle array is permanently attached to the bottom portion of the substrate; and

a detector that receives signals emitted by the plurality of fluorophore sensors for calculating the concentration of the at least one analyte present in the fluid sample of the patient, and transmitting the concentration to an external device for diagnosis and evaluation of proposed treatments.

10. The device of claim 9 , wherein the at least one polymeric material is polyacrylamide.

11. The device of claim 9 , wherein the fluid sample is selected from the group consisting of interstitial fluid and blood.

12. The device of claim 9 , wherein the bottom portion of the substrate comprises an adhesive for affixing the substrate to the epidermal tissue of the patient.

13. The device of claim 9 , wherein the detector is selected from the group consisting of a microfluorometer, a filter fluorometer or a spectrofluorometer.

14. The device of claim 9 wherein each fluorophore sensor comprises at least one fluorophore selected from the group consisting of fluorescein, rhodamine, eosin, Oregon Green, Texas Red, coumarin derivatives, cyanine, indocarbocyanine, oxacarbocyanine, thiacarbocyanine, merocyanine, squaraine derivatives, pyridyoxazole, nitrobenzoxadiazole, benzoxadiazole, anthraquinones, pyrene derivatives, Nile Red, Nile Blue, cresyl violet, oxazine, proflavin, acridine orange, acridine yellow, auramine, crystal violet, malachite green, porphyrin, phtalocyanine, bilirubin, boronate, and combinations thereof.

15. The device of claim 9 , wherein the at least one analyte present in the fluid sample of the patient is glucose.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2019
From: LEDDEN, DAVID
To: SIEMENS HEALTHCARE DIAGNOSTICS INC.
Reel/Frame 048060/0497 →
Continuity (3)
Provisional Application 62363577 · Jul 18, 2016
Provisional Application 62363572 · Jul 18, 2016
Related Publication 20210282709A1 · Sep 16, 2021
Cited By (2)
US 12,186,515 US 12,714,838